Evaxion A/S

Healthcare · Biotechnology · Denmark

Last price 2.9 USD (Oct 30, 2026, 3:45 PM EDT) · Market cap 24.19M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin...